NCTN—View from a Lead Academic Site/Cancer Center

Nancy E. Davidson, MD
Hillman Professor of Oncology
Director, University of Pittsburgh Cancer Institute and UPMC CancerCenter
University of Pittsburgh Cancer Institute (UPCI)

- 320 faculty members from 42 academic departments at University of Pittsburgh
- Clinical research and care through UPMC hospitals and cancer centers
Thriving UPMC CancerCenter Network

Stanley Marks, MD

Peter Ellis, MD

Dwight Heron, MD

Charles Bogosta

Ireland

Italy

Singapore
Accrual to Interventional Clinical Trials at UPCI UPMC CancerCenter (2004 – 2013)
National Clinical Trials Network (NCTN)

• Group Statistician, NRG
• NRG Biostatistical Office headquartered at University of Pittsburgh

Costantino

Lead Academic Participating Site (LAPS) (CA180844)

Brufsky

Early Therapeutics Clinical Trials Network Site (UM1CA099168)

Chu
Cooperative Groups Consolidation
UPCI Participated in 8 Cooperative Groups
Cooperative Groups Consolidation

ECOG-ACRIN
cancer research group
Reshaping the future of patient care

NRG ONCOLOGY

Alliance
for Clinical Trials in Oncology

SWOG
Leading cancer research. Together.

CureSearch
Children’s Oncology Group

UPCI Participating in 4 Cooperative Groups
Potential Advantages for LAPS

- Single grant—streamlined finances and administration
- Use of NCI CIRB
- Enhanced case reimbursement
- Provided internal mandate to assemble a steering committee led by UPCI AD for Clinical Investigation to oversee NCTN accruals and allocate resources—better integration
Potential Disadvantages for LAPS

- Shifting focus and loyalty from legacy to new cooperative groups
- Maintaining engagement of LAPS leaders with scientific leadership of new cooperative groups
- Encouraging NCTN involvement for young investigators given lack of opportunity to “lead”
- Financial penalty for “overaccrual”
What We Must Consider…..

- Impact of a more centrally directed NCTN in the field
- How a goal of smaller biologically based trials will be implemented in the community
- Interactions between and roles of the component parts to advance the clinical trials agenda—cooperative groups, LAPS, NCORPs, ET-CTN, SPOREs, CCSGs, etc